CoChat

Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity

Open access
Mirković, Bojana, Markelc, Boštjan, Butinar, Miha, Mitrović, Ana, Sosič, Izidor, Gobec, Stanislav, Vasiljeva, Olga, Turk, Boris, Čemažar, Maja, Serša, Gregor, Kos, Janko · 2015 · Oncotarget
Cited by 66

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Bojana Mirković 1,* , Boštjan Markelc 2,* , Miha Butinar 3,* , Ana Mitrović 1 , Izidor Sosič 1 , Stanislav Gobec 1 , Olga Vasiljeva 3 , Boris Turk 3,4,5 , Maja Čemažar 2 , Gregor Serša 2 and Janko Kos 1,6 1 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia 2 Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia 3 Department of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, Ljubljana, Slovenia 4 Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, Ljubljana, Slovenia 5 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia 6 Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia * These authors have equally contributed to this work Correspondence to: Bojana Mirković, email: // Janko Kos, email: // Keywords : nitroxoline, cathepsin B, tumor invasion, angiogenesis, metastasis Received : November 01, 2014 Accepted : March 05, 2015 Published : March 30, 2015 Abstract Cathepsin B is a ubiquitously expressed lysosomal cysteine protease that participates in protein turnover within lysosomes. However, its protein and activity levels have been shown to be increased in cancer. Cathepsin B endopeptidase activity is involved in the degradation of extracellular matrix, a process that promotes tumor invasion, metastasis and angiogenesis. Previously, we reported an established antibiotic nitroxoline as a potent and selective inhibitor of cathepsin B. In the present study, we elucidated its anti-tumor properties in in vitro and in vivo tumor models. Tumor and endothelial cell lines with high levels of active cathepsin B were selected for functional analysis of nitroxoline in vitro . Nitroxoline significantly reduced extracellular DQ-collagen IV degradation by all evaluated cancer cell lines using spectrofluorimetry. Nitroxoline also markedly decreased tumor cell invasion monitored in real time and reduced the invasive growth of multicellular tumor spheroids, used as a 3D in vitro model of tumor invasion. Additionally, endothelial tube formation was significantly reduced by nitroxoline in an in vitro angiogenesis assay. Finally, nitroxoline significantly abrogated tumor growth, angiogenesis and metastasis in vivo in LPB fibrosarcoma and MMTV-PyMT breast cancer mouse models. Overall, our results designate nitroxoline as a promising drug candidate for anti-cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3699

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 66

Metadata

Authors
Mirković, B., Markelc, B., Butinar, M., Mitrović, A., Sosič, I., Gobec, S., Vasiljeva, O., Turk, B., Čemažar, M., Serša, G., & Kos, J.
Venue
Oncotarget
Published
2015-03-30
Volume
6
Issue
22
Pages
19027-19042
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1826848231
Cited by
66
References
5
FWCI
2.45
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. https://app.cochat.ai/papers/10.18632/oncotarget.3699
The paper
Mirković, B., Markelc, B., Butinar, M., Mitrović, A., Sosič, I., Gobec, S., Vasiljeva, O., Turk, B., Čemažar, M., Serša, G., & Kos, J. (2015). Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget. https://doi.org/10.18632/oncotarget.3699

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.